As PhilHealth Board, under Resolution No. 1013 s-2007, approved the provision of financial, administrative and technical support for the operations of the Antimicrobial Resistance Surveillance Program of the Department of Health (DOH-ARSP), PhilHealth is hereby lifting the implementation of Circular No. 04, s. 2007 providing for indefinite postponement of the reimbursement of certain drugs namely, cefepime, gatifloxacin, meropenem, piperacillin, tazobactam and vancomycin, which were used in PhilHealth accredited tertiary hospitals with DOH-ARSP accreditation.

It is reiterated that reimbursement of the above-mentioned drugs shall be made only when used in PhilHealth accredited tertiary hospitals with DOH-ARSP accreditation (as stipulated in PhilHealth Circular No. 15, s. 2006, as amended by Circular No. 18, s. 2006).

Should DOH revise the drugs listed under the program prior to the date of effectivity of this circular, PhilHealth shall immediately notify all stakeholders.

This Circular shall take effect on all claims with admission dates starting July 1, 2008.

All other issuances inconsistent herein are hereby repealed and modified accordingly.